Clinical Trials Browser

Phase 2 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × ofatumumab × Clear all

NCT03136146 2026-02-17

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02199184 2024-06-11

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 2 Completed

14 enrolled 10 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01363128 2021-05-03

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2 Completed

72 enrolled 10 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02419469 2018-06-11

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2 Terminated

1 enrolled 4 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01520922 2017-01-19

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Phase 2 Completed

99 enrolled 27 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Neoplasms, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma